The webpage presents an interview with Dr. Arne Solheim, a Norwegian endocrinologist described as a leading expert in diabetes treatment. The content focuses on his critique of conventional diabetes therapies and promotion of an alternative solution. Key points include: 1. **Critique of Metformin-Based Treatments**: Dr. Solheim asserts that metformin, a standard medication for type 2 diabetes, causes severe harm. He claims it elevates insulin levels abnormally, leading to complications such as organ damage (liver, kidneys), cancer (28% of diabetics), hypertension, cardiovascular issues, and accelerated aging. He attributes these effects to insulin’s toxic impact on cells and blood vessels, likening it to magesyre (gastric acid) corroding internal organs. Additional adverse effects listed include gastrointestinal disorders, cirrhosis, kidney stones, and oncological diseases. Dr. Solheim accuses healthcare professionals of prioritizing financial interests over patient welfare by prescribing metformin, which he claims offers only temporary symptom relief while exacerbating long-term health risks. 2. **Diabetes Complications**: The article outlines severe consequences of untreated or inadequately managed diabetes, including blindness (due to retinal hemorrhages), kidney failure (from sugar-clogged ureters), joint immobility (loss of synovial fluid), nerve damage (leading to mental health deterioration), and skin decay (progressing to gangrene). These complications are linked to vascular deterioration caused by high blood sugar, which Dr. Solheim compares to the sugaring of candied fruits, rendering blood vessels brittle. 3. **Alternative Treatment: Glyco Forte**: The article promotes Glyco Forte, developed in 2015 by the California Institute for Endocrinology. This product is described as a “natural anti-diabetic complex” containing 60+ active ingredients, including vitamins, minerals, and 28 global herbal extracts. Unlike metformin, Glyco Forte is claimed to both lower blood sugar and strengthen the body. Dr. Solheim states it has a 96% “recovery rate” from type 2 diabetes, citing patient testimonials like that of Vibeke Bø from Oslo (details omitted in the excerpt). The treatment is framed as a systemic solution, contrasting with what he describes as the fragmented, harmful nature of conventional therapies. 4. **Call to Action**: The content emphasizes the urgency of abandoning metformin, warning that its use hastens organ failure and death. Patients are advised to avoid physicians prescribing metformin and seek alternatives, with Glyco Forte positioned as the recommended option. The narrative underscores diabetes as a life-threatening, systemic disease requiring comprehensive management. The article’s structure combines medical commentary with promotional language, contrasting conventional medicine’s shortcomings with the purported efficacy of Glyco Forte. No regulatory, clinical, or independent verification of its claims is mentioned in the provided text.